Clinical trials: Small-cell Lung Cancer
NSCLC, Crizotinib
Descriptive Observational Study ALK-2016-CPHG
Descriptive Observational Study. Characteristics Of ALK-positive and ROS1-positive Adults Patients Non-Small Cell Lung Cancer (NSCLC) Treated With Crizotinib Within General Hospitals
- Conditions
- NSCLC, Crizotinib, ALK Gene Rearrangement or ROS1 Gene Rearrangement
- Trial name
- ALK2016CPHG (NCT03718117)
- Where
- 26 sites in France
- Volunteers
- 73 people
- Sponsor
- Pfizer
Lung Cancer
Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs.
- Trial name
- NCT00062010
- Testing
- interferon alpha, 13-cis-retinoic acid, paclitaxel
- Where
- 73 sites in United States
- Volunteers
- 37 people
- Sponsor
- Eastern Cooperative Oncology Group
Solid Tumors, Cancer
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.
- Trial name
- NCT00940225
- Testing
- Cabozantinib
- Where
- 47 sites in United States, Belgium and 3 more
- Volunteers
- 730 people
- Sponsor
- Exelixis
Non Small Cell Lung Cancer
Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
Phase II, single-arm, open-label multicenter study that assesses feasibility, safety and efficacy of combined neoadjuvant chemotherapy and immunotherapy with Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV…
- Trial name
- NCT03081689
- Testing
- Nivolumab 360 mg, Paclitaxel 200mg/m2, Carboplatin AUC 6
- Where
- 24 sites in Spain
- Volunteers
- 46 people
- Sponsor
- Spanish Lung Cancer Group
Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms
This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091
The main objective of this study is to determine the biodistribution and intra-tumor accumulation of [89Zr]Zr-BI 754111 at baseline and its change upon treatment
- Trial name
- NCT03780725
- Testing
- BI 754111, [89Zr]Zr-BI 754111, BI 754091
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- Boehringer Ingelheim
Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
To evaluate the tolerability and safety of axalimogene filolisbac 1 x 10^10 colony forming units (cfu) administered with prophylactic premedication in repeating 3-dose study cycles in women with persistent, metastatic, or…
- Conditions
- Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer, Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma
- Trial name
- NCT02164461
- Testing
- Axalimogene filolisbac
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Advaxis, Inc.
Lung Cancer
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
This trial will look at 2 different drug combinations that have well known safety profiles and are known to be active against non small cell lung cancer and combine them with bevacizumab, an experimental drug that has shown…
- Trial name
- NCT00456261
- Testing
- Pemetrexed, Gemcitabine, Bevacizumab
- Where
- 18 sites in United States
- Volunteers
- 110 people
- Sponsor
- SCRI Development Innovations, LLC
Lung Cancer, Non-Small Cell
Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer
The main purpose of this study is to determine whether the combination of pazopanib and pemetrexed is safe and effective in the treatment of advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT00871403
- Testing
- pazopanib and pemetrexed, pemetrexed and cisplatin
- Where
- 2 sites in Denmark, United Kingdom
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer NSCLC
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
This is a randomized, double-blind, multi-center, global Phase II study to determine the efficacy and safety of Durvalumab plus Olaparib combination therapy compared with Durvalumab monotherapy as maintenance therapy in patients…
- Trial name
- ORION (NCT03775486)
- Testing
- Durvalumab, Olaparib, Nab-paclitaxel+carboplatin
- Where
- 68 sites in United States, Belgium and 10 more
- Volunteers
- 401 people
- Sponsor
- AstraZeneca
Lung Cancer
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00984542
- Testing
- bendamustine hydrochloride
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
This phase II trial is studying how well ABI-007 works in treating patients with persistent or recurrent cervical cancer. Drugs used in chemotherapy, such as ABI-007, work in different ways to stop the growth of tumor cells…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT00309959
- Testing
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Laboratory Biomarker Analysis
- Where
- 26 sites in United States
- Volunteers
- 37 people
- Sponsor
- Gynecologic Oncology Group
Neoplasms
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
This phase IB trial aims to identify anticancer activity of GSK3052230 in subjects with malignancies with abnormal dependence on FGF pathway signaling.
- Trial name
- NCT01868022
- Testing
- GSK3052230, paclitaxel, carboplatin
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 65 people
- Sponsor
- GlaxoSmithKline
Metastatic Non-small Cell Lung Cancer
PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer
This study will evaluate the safety of PD-1 knockout engineered T cells in treating metastatic non-small cell lung cancer. Blood samples will also be collected for research purposes.
- Trial name
- NCT02793856
- Testing
- Cyclophosphamide, PD-1 Knockout T Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sichuan University
Small-cell Lung Cancer
SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy
This is a multi-center, open-label, phase II study of intravenous (IV) SHR-1210 at 200mg,q2w in combination with Apatinib at one dose (375mg).
- Trial name
- PASSION (NCT03417895)
- Testing
- SHR-1210, Apatinib
- Where
- 2 sites in China
- Volunteers
- 59 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-Small Cell Lung Cancer
LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
A single-Arm, open-label, multi-center, phase I/II study in which the pharmacokinetics, safety, tolerability and efficacy of LDK378 will be assessed in adult Chinese patients with locally advanced or metastatic NSCLC harboring a…
- Trial name
- NCT02040870
- Testing
- LDK378
- Where
- 15 sites in China
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.
- Conditions
- Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma, Melanoma, Other Solid Tumors
- Trial name
- NCT02711345
- Testing
- LTT462
- Where
- 7 sites in United States, Germany and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Limited Stage Small Cell Lung Cancer
Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer
This phase II trial is studying how well giving tirapazamine together with cisplatin, etoposide, and radiation therapy works in treating patients with limited-stage small cell lung cancer.
- Trial name
- NCT00066742
- Testing
- tirapazamine, cisplatin, etoposide
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Oligometastatic Disease
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy…
- Trial name
- NCT05846646
- Testing
- IMSA101, Immune checkpoint inhibitor, PULSAR
- Where
- 9 sites in United States
- Volunteers
- 6 people
- Sponsor
- ImmuneSensor Therapeutics Inc.
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Background: The current standard of care for advanced lung cancer and cancers of the thymus consists primarily of chemotherapy treatment.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic
- Trial name
- NCT01306045
- Testing
- AZD6244, MK-2206, Lapatinib
- Where
- United States
- Volunteers
- 647 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.
- Trial name
- NCT00191139
- Testing
- gemcitabine, docetaxel, cisplatin
- Where
- 15 sites in United States, Argentina and 2 more
- Volunteers
- 64 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.